Subscribe free

Cytoreductive Surgery & Peritoneum ·

Advances in treating peritoneal oligometastasis in gastric cancer

Peritoneal metastasis from gastric cancer significantly impacts prognosis, but advancements in diagnostic and therapeutic strategies are transforming patient outcomes. A peritoneal cancer index (PCI) threshold of ≤6 identifies patients with oligometastasis who may benefit from aggressive therapies. Cytoreductive surgery coupled with hyperthermic intraperitoneal chemotherapy remains essential for curative intent. Emerging techniques like normothermic and pressurized intraperitoneal aerosol chemotherapy are broadening treatment options, emphasizing individualized approaches for improved survival rates in previously challenging cases.

Review by Kim HI and Badgwell BD in J Gastric Cancer

Copyright © 2025. Korean Gastric Cancer Association.

read the whole article in J Gastric Cancer

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →